Multiple Myeloma News
Only 26% of MM RCTs Report Racial Composition of Enrolled Patients
Despite improvement in overall survival for patients with multiple myeloma, racial minorities benefit less from these survival gains. Earlier research shows racial minorities are under-represented in multiple myeloma clinical trials, with scarce reporting of their...
Selected Journal Articles for the Week of January 18th
Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice Background: We have performed a head to head comparison of all-oral triplet...
Delaying Daratumumab until Second Line in Transplant-ineligible Patients More Cost Effective
A study published in the Journal of Clinical Oncology suggests that using daratumumab in the first-line setting for transplant-ineligible patients may not be cost-effective under current pricing. the cost of daratumumab would need to be decreased by 67% for first-line...
Melflufen Plus Dexamethasone in RRMM Shows Durable Response
Updated survival data for the Phase II study O‐12‐M1 of melphalan flufenamide (melflufen) plus dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) with two or more prior lines of therapy was published in the British Journal of Haematology. The...
Oncopeptides Enrolls 1st Patient in Phase 3 LIGHTHOUSE Study
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), today announced that the first patient has been dosed in the phase 3 LIGHTHOUSE study, evaluating the efficacy and safety of a triple combination therapy with melflufen plus dexamethasone and subcutaneous daratumumab...
FDA Approval of Selinexor After At Least One Prior Therapy
The U.S. Food and Drug Administration (FDA) has approved XPOVIO® (selinexor) an oral Selective Inhibitor of Nuclear Export (SINE) medicine, in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at...
NICE Recommends Isatuximab + POM/Dex for people with difficult-to-treat multiple myeloma
NICE has recommended Isatuximab for people with difficult-to-treat multiple myeloma (MM). Isatuximab, administered as an intravenous infusion, plus pomalidomide and dexamethasone is recommended for use within the Cancer Drugs Fund as an option for treating relapsed...
Hypercalcemia Indicates Poor Outcomes in Newly Diagnosed Multiple Myeloma (NDMM)
A new study published in Cancer Medicine demonstrates that Hypercalcemia is associated with poor rates of survival in patients with newly diagnosed myeloma (NDMM). The researchers retrospectively evaluated the prognostic impact and mechanism of hypercalcemia in 357...
Accurate Identification of Patients with SMM at Highest Risk of Developing MM Remains Difficult
The accurate identification of patients with SMM at highest risk of developing MM remains difficult.
FDA Lifts Clinical Hold on MELANI-01 Study Evaluating UCARTCS1
Cellectis announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Phase 1 MELANI-01 trial evaluating the UCARTCS1 product candidate for the treatment of patients with relapsed or refractory multiple myeloma (MM). Cellectis worked...
Other Oncology News
Additional Myeloma News
Powered by:
- Oncopeptides Enrolls the First Patient in the Phase 3 LIGHTHOUSE Combination Study in Multiple Myeloma
- FDA Approves Karyopharm’s Xpovio To Treat Multiple Myeloma After At Least One Prior Therapy
- Janssen Initiates Rolling Submission of a Biologics License Application to U.S. FDA for BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractory Multiple Myeloma
- FDA Approves Selinexor For Refractory Or Relapsed Multiple Myeloma
- ONJ Incidence Determined by S0702
- Cerecor Announces First Patient Dosed in a Phase 1b Clinical Trial of CERC-007 for the Treatment of Relapsed or Refractory Multiple Myeloma
- Karyopharm Announces National Comprehensive Cancer Network® Adds Three XPOVIO® (selinexor) Treatment Regimens to Its Clinical Practice Guidelines in Oncology for Multiple Myeloma
- ASH 2020: GPRC5D Is a New Target of Interest for Multiple Myeloma
- Year in Review: Hematologic Malignancies
- Sequencing Study from Roswell Park Highlights Previously Unknown Myeloma Resistance Mechanisms
Join Our Community
By joining the MYELOMA360 community, you will receive regular updates with news, information, insights and expert opinions.
Of course, you can opt out at any time.